MetaCap

Stoke Therapeutics (STOK) vs Vera Therapeutics (VERA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Stoke Therapeutics (STOK) has outperformed Vera Therapeutics (VERA) over the past year, losing 8.6% versus a loss of 10.6%. Over five years, STOK leads with a +6.8% price change compared with -15.2% for VERA. Vera Therapeutics is the larger company by market cap ($1.84 billion vs $1.75 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

STOK-8.62%VERA-10.58%
+102%+36%-29%
Nov 21, 20251 yearNov 20, 2026
STOK-3.56%VERA-18.43%
+80%-8%-96%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

STOK versus VERA key metrics
MetricSTOKVERA
Share price$26.81$25.45
Market cap$1.75B$1.84B
1-day change-0.45%-4.86%
YTD return-15.53%-49.74%
1-year return-8.62%-10.58%
5-year return+6.77%-15.17%
EPS (TTM)$-3.81$-5.90
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$184.42M—
Revenue growth (YoY)+404.50%—
Net income (latest FY)$-6.88M$-299.62M
Operating margin-11.16%—
Net margin-3.73%—
52-week high$40.22$56.05
52-week low$22.05$25.08
Distance from 52-week high-33.34%-54.59%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+73.00%+180.39%
Average volume1.02M1.95M
Shares outstanding65.41M72.30M
Employees170362
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Stoke Therapeutics

STOK stock →

Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression.

Health Care · Biotechnology: Pharmaceutical Preparations · 170 employees

About Vera Therapeutics

VERA stock →

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 362 employees

STOK vs VERA FAQ

Which is bigger, Stoke Therapeutics or Vera Therapeutics?

Vera Therapeutics (VERA) is larger, with a market capitalization of $1.84B compared with $1.75B for Stoke Therapeutics (STOK).

Which stock has performed better over the past year, STOK or VERA?

STOK returned -8.62% over the past 12 months, compared with -10.58% for VERA (price return, excluding dividends). Past performance does not predict future results.

Are Stoke Therapeutics and Vera Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons